Search
Physician Excellence in Cancer Care Awards
… status quo, and leads with clarity and courage. "Dr. Emese Zsiros has a rare and remarkable ability to transform vision … bold vision and innovation.” Bio Reference Emese Zsiros, MD, PhD, FACOG Professor of Oncology Shashi Lele, MD, … Department of Gynecologic Oncology Meet the nominees Emese Zsiros, MD, PhD, FACOG Kenan Onel, MD, PhD Khurshid Guru, MD …
Page with Layout
Medical Therapy for Cervical Cancer
… Medical Therapy for Cervical Cancer Dr. Emese Zsiros has extensive knowledge in the immuntherapy treatment … of treatments best for you and your cancer. Dr. Emese Zsiros has extensive knowledge in the immuntherapy treatment …
Blog Post
Cancer Innovations: Prioritizing quality of life while treating cancer
… the Cell Stress and Biophysical Therapy Program, and Emese Zsiros, MD, PhD, FACOG , Director of Research in the … more — and better quality — time with their loved ones Dr. Zsiros has spent the past several years researching the use … was 8-15%. The combination has a synergistic effect,” Dr. Zsiros says. “The typical treatments for ovarian cancer …
News
Roswell Park Team Assesses Addition of Complement Inhibitor Drug to Immunotherapy for Ovarian Cancer
… it has been evaluated for the treatment of cancer. Emese Zsiros, MD, PhD, FACOG , serves as principal investigator for … Research Project Grant (R01) awarded to Drs. Zsiros and Segal. “The tumor microenvironment of ovarian … cancer strongly suppresses the immune system,” says Dr. Zsiros, who is Chair of the Department of Gynecologic …
News
Roswell Park Researchers Uncover Clues to Immunotherapy Response in Patients with Recurrent Ovarian Cancer
Blog Post
Cancer Innovations: New initiative reduced prescribed opioids by 45%
Cancer Types
Recurrent Ovarian Cancer
Clinical Trial
A Phase I First-In-Human, Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors
Clinical Trial
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY FOR LNCB74, A B7-H4 TARGETED ANTIBODY DRUG CONJUGATE, AS MONOTHERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Page with Layout
McLean Laboratory Publications
… JAMA , September 2025 Authors: Frederick PJ, Seshadri M, Zsiros E, McLean K. Citation: 2025;334(17):1511–1512. … 41334034; PMCID: PMC12668522. Frederick PJ, Seshadri M, Zsiros E, McLean K. Reflections on Medical Trainee Unions and … Stewart D, Thaker PH, Vargas R, Hendrickson AW, Werner TL, Zsiros E, Dwyer MA, Hang L. NCCN Guidelines® Insights: …